AGY:LSE-Allergy Therapeutics (GBX)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | LSE

Last Closing Price

GBX 19.50

Change

-1.25 (-6.02)%

Market Cap

GBX 0.13B

Volume

0.18M

Avg Analyst Target

N/A

Avg User Target

GBX
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


AGY Stock Forecast & Price:
Based on the Allergy Therapeutics stock forecasts from 0 analysts, the average analyst target price for Allergy Therapeutics is not available over the next 12 months. Allergy Therapeutics’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Allergy Therapeutics is Neutral, which is based on 5 positive signals and 6 negative signals. At the last closing, Allergy Therapeutics’s stock price was GBX 19.50. Allergy Therapeutics’s stock price has changed by -6.02% over the past week, -11.36% over the past month and -22.00% over the last year.

No recent analyst target price found for Allergy Therapeutics
No recent average analyst rating found for Allergy Therapeutics

About Allergy Therapeutics (AGY:LSE)

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to g ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-04 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HIK:LSE Hikma Pharmaceuticals PLC

+32.50 (+2.00%)

GBX3.57B 1,088.26 5.39
INDV:LSE Indivior PLC

+5.20 (+1.71%)

GBX2.13B 1,603.16 7.23
HCM:LSE HUTCHMED China Ltd

+21.25 (+9.63%)

GBX1.91B 17.41 -5.27
APH:LSE Alliance Pharma plc

N/A

GBX0.60B 11,200.00 19.07
BXP:LSE Beximco Pharmaceuticals Limite..

-3.00 (-4.26%)

GBX0.60B 640.91 0.09
AMYT:LSE Amryt Pharma plc

N/A

GBX0.46B N/A 260.86
BMK:LSE Benchmark Holdings plc

N/A

GBX0.33B N/A 14.50
ANCR:LSE Animalcare Group Plc

N/A

GBX0.16B 3,350.00 17.42
EAH:LSE Eco Animal Health Group Plc

-3.50 (-3.10%)

GBX0.08B 1,412.50 3.05
VLG:LSE Venture Life Group plc

N/A

GBX0.04B 1,675.00 9.78

ETFs Containing AGY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -39.53% 47% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.53% 47% F 14% F
Trailing 12 Months  
Capital Gain -22.00% 64% D 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.00% 64% D 31% F
Trailing 5 Years  
Capital Gain -22.77% 64% D 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.77% 57% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain 15.99% 57% F 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.99% 43% F 72% C-
Risk Return Profile  
Volatility (Standard Deviation) 64.20% 50% F 23% F
Risk Adjusted Return 24.90% 50% F 49% F
Market Capitalization 0.13B 53% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 53.13 82% B- 43% F
Price/Book Ratio 2.43 20% F 27% F
Price / Cash Flow Ratio 15.91 20% F 26% F
EV/EBITDA 338.33 7% F 1% F
Management Effectiveness  
Return on Equity -9.47% 47% F 20% F
Return on Invested Capital 6.55% 73% C 61% D-
Return on Assets -2.90% 47% F 20% F
Debt to Equity Ratio 5.05% 88% B+ 87% B+
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.60 13% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.